How to use the speech recognition tool?
A Study to Determine the Safety and Efficacy of RenexusÂ® in Macular Telangiectasia Type 2
A Study to Determine the Safety and Efficacy of RenexusÂ® in Macular Telangiectasia Type 2.
Status of the trial: Active, Not recruiting
Orphan Drug Recognition: NA
- Opening Date: 2018-02-06
- Closing Date: 2022-03-31
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
- Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-Eye